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We have constructed a series of retroviral vectors in which the expression of antisense RNA targeted at the full length
coding sequence of HIV-1 tat or rev was driven by three different promoters and in the context of double-copy or single-
copy vectors. Jurkat cells transduced by these vectors were shown to express the expected tat or rev antisense RNA
without alteration in cell proliferation or surface CD4 expression. After challenge with HIV, four patterns of protection were
identified, with the degree of protection being determined primarily by the design of the expression system. In those patterns
showing long-term complete protection, we could detect no HIV p24 in the culture supernatants or in the cells, and no HIV
RNA or HIV proviral DNA (by PCR), during a 23-week follow-up. Experiments designed to rescue any live virus still formed
in the culture after 20 weeks’ challenge demonstrated that, with some constructs, infectious virus could no longer be
isolated, while with other constructs, only a low level of infectious virus was still being formed and providing a continuing
virus challenge, although all other markers of infection remained undetectable. Our results demonstrated that antisense
RNA expression driven by tRNA promoter in the context of a double-copy vector conferred better long-term protection
against HIV infection compared to that driven by HIV LTR or MLV LTR promoters, and that the optimized vectors may be
useful in developing a gene therapy against HIV-1 infection and AIDS. q 1996 Academic Press, Inc.
INTRODUCTION al., 1994). (2) Ribozymes: including hammerhead ribozymes
(Sarver et al., 1990; Weerasinghe et al., 1991; Dropulic et al.,
CD4/ T cell deletion and the fast turnover of CD4/ T
1992) or hairpin ribozymes (Ojwang et al., 1992; Yu et al.,
cells in HIV-infected patients result mainly from continu-
1993, 1995; Yamada et al., 1994) targeted at the 5* untrans-
ing de novo HIV infection of permissive CD4/ T cells. lated leading sequence of HIV mRNA or packaging se-
This gradually leads to the exhaustion of the regenerative quence (Sun et al., 1994). (3) Antisense RNA targeted at
capacity of the immune system and development of AIDS mRNA of gag (Sczakiel and Pawlita, 1991; Chatterjee et al.,
(Wei et al., 1995; Ho et al., 1995). Intracellular immuniza- 1992), tat (Rhodes and James, 1990; Sczakiel et al., 1992; Lo
tion by introducing HIV resistance genes into susceptible et al., 1992), rev (Sczakiel et al., 1992), env, or other HIV
cells offers a potential way to break the cycle of HIV mRNAs (Rhodes and James, 1991; Joshi et al., 1991). (4) The
infection, replication, and CD4/ T cell depletion. combination of two of the above effector RNA sequences
The effector molecules used for intracellular immunization (Homann et al., 1993; Crisell et al., 1993; Lo et al., 1992).
against HIV can be divided into two major groups—proteins Using RNA as effector molecules could avoid possible dis-
and RNAs. Protein effectors which have been shown to advantages associated with constitutive expression of for-
inhibit HIV infection and replication include transdominant eign proteins in vivo. For example, if expression is not regu-
mutants of tat (Green et al., 1989; Pearson et al., 1990; lated and not restricted to virus-infected cells, the foreign
Bahner et al., 1993), rev (Malim et al., 1989; Bevec et al., proteins may be processed inside the cells and presented
1992; Bahner et al., 1993; Furuta et al., 1995), gag (Trono et through MHC I molecules and trigger CTL which may de-
al., 1989), and env (Freed et al., 1992), as well as single- stroy any antigen-expressing cells (Hill and Ploegh, 1995).
chain antibody or Fab fragments targeted at gp120 (Chen Tat and rev are viral regulatory proteins indispensable
et al., 1994), tat (Mhashilkar et al., 1995), and reverse tran- for the replication of HIV-1 (Fisher et al., 1986; Dayton et
scriptase (Maciejewski et al., 1995). Three types of RNA al., 1986; Feinberg et al., 1986) and important for the
effector molecules have been used for intracellular immuni- transition from latent to productive infection (Peng et al.,
zation against HIV infection. (1) Decoy RNA of TAR (Sullenger 1995). Blocking the production or activity of tat or rev
et al., 1990a, 1991; Lisziewicz et al., 1993) or RRE (Lee et may not only cripple the replication and activation of HIV,
but also inhibit the pathogenic effects associated with
tat, such as induction of apoptosis in uninfected lympho-1 To whom correspondence and reprint requests should be ad-
dressed. Fax: (08) 222 3538. cytes (Li et al., 1995), immunosuppressive effects (Viscidi
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et al., 1989; Cupp et al., 1993; Chirmule et al., 1995), from HIV infectious clone pNL43 (Adachi et al., 1986;
from AIDS Research and Reference Reagent Program,stimulation of growth of Kaposi’s sarcoma (Ensoli et al.,
1990, 1994), and enhanced replication of human cyto- NIAID, NIH) using the strategy described before (Peng
et al., 1995). Human tRNAmet promoter was PCR amplifiedmegalovirus, an opportunistic pathogen often associated
with AIDS (Ho et al., 1990). from cellular DNA isolated from human Jurkat cells. All
the PCR products were cloned into pBluescript II (KS0)Most of the intracellular immunization studies listed
above only evaluated anti-HIV effects by measuring p24 (Stratagene). Their sequences were subsequently veri-
fied by DNA sequencing. The cDNA of HIV-1 tat and revlevels in a short-term culture, and in many cases, inhibi-
tion was partial and transient. None of these studies were cleaved from pCDM-tat and pCDM-rev, respectively
(Peng et al., 1995).monitored the synthesis of HIV proviral DNA in a long-
term follow-up. HIV inhibition in a short-term culture may The double-copy retrovirus vector was constructed us-
ing a strategy similar to that described by Hantzopoulosnot reflect the in vivo situation because of the lengthy
time scale of HIV pathogenesis in vivo. In addition, inhibi- et al. (1989) and Sullenger et al. (1990b). Briefly, a double-
strand oligonucleotide (5* cta gct taa gta agc cca ttt gaation of p24 production may not correlate with the sup-
pression of proviral DNA synthesis, which is a more sen- ttc atc gat ctc gag gga tcc gcg gcc gcg ttt ttt ttt ggg ccc
g 3*) containing 21 nucleotides of the MLV U3 sequence,sitive indicator of viral infection.
The efficiency of protection conferred by intracellular restriction enzyme sites (EcoRI– ClaI–XhoI–BamHI–
NotI), and a RNA polymerase III transcription terminationimmunization against HIV may be determined by several
factors. These include the chosen targets within the HIV signal (RNA-P III TT) was inserted into the NheI site (31
bp from the 5* end of the MLV U3) in the 3* LTR of pLXSN,genome; the nature, length, and expression level of ef-
fector molecules; and perhaps more importantly, the ac- from which the original polylinker had been deleted by
restriction enzyme digestion and religation. Thus, the re-cessory or flanking sequence of the effector molecules.
The latter may be determined primarily by the driving sultant vector contained a polylinker and a RNA-P III TT
in the U3 region (52 bp from the 5* end) of the 3* LTR.promoter. Three promising promoters that have been
used to drive the expression of anti-HIV genes are the The tRNA promoter or HIV-1 LTR promoter and cDNA for
tat or rev antisense RNA were subsequently inserted intoretroviral vector LTR promoter (MLV LTR), the HIV LTR
promoter, and human tRNA promoters. However, the rel- the polylinker upstream of RNA-P III TT. Unless stated
otherwise, all the DNA cloning was performed accordingative merits of these promoters have not been directly
compared. Furthermore, all the antisense RNA templates to the established procedures (Sambrook et al., 1989).
used for tat, and most of those for rev, represented only
part of the coding sequence. The potential of antisense Cell culture, transfection, and transduction
RNA transcribed from the full length coding sequence
of tat or rev, with or without the untranslated leading The amphotropic retrovirus packaging cell line PA317
(Miller and Buttimore, 1986) (from ATCC) and human cer-sequence, remains unknown.
In this report, we used antisense RNA targeted at the full vical epithelial carcinoma cell line HeLa were cultured
in DMEM (Gibco) supplemented with 10% fetal calf serumlength coding sequences of tat or rev as effector molecules.
We also included the untranslated leading sequence pres- (FCS, from CSL), 12 ng/ml penicillin, 160 ng/ml genta-
mycin, and 2 mM L-glutamine. Human CD4/ lymphoident in all the HIV-1 transcripts as part of the target for
antisense interference in some of our constructs. We have cell line Jurkat cells (from ATCC) were grown in RPMI-
1640 (from Gibco) with 10% FCS, 12 ng/ml penicillin, 160compared in parallel a series of vectors in which the expres-
sion of antisense RNA was placed under the control of the ng/ml gentamycin, and 2 mM L-glutamine. All the cells
were free of Mycoplasma sp.HIV LTR promoter, the RNA polymerase III promoter, or the
MLV promoter and in the context of double-copy or single- The recombinant retroviral vectors were transfected
into PA317 cells using the calcium phosphate precipita-copy retroviral vectors. We report here that tat and rev anti-
sense RNA expressed under the control of human tRNAmet tion procedure (Graham and Van der Eb, 1973). Forty-
eight hours after transfection the conditioned mediumpromoter in the context of a double-copy vector conferred
long-term protection against HIV infection. The efficiency of containing the defective recombinant virus was collected
by centrifuge at 4000 rpm for 10 min and stored at 0707.protection seemed to be primarily determined by the struc-
ture of antisense RNA, rather than by levels of expression. To select the stably transfected packaging cells, the cells
were cultured in selective medium (DMEM growth me-
dium containing 400 mg/ml active Geneticin, from Gibco)MATERIALS AND METHODS
with medium changed every 3–4 days thereafter. Resis-
Construction of retroviral vectors
tant cells grew up 2 to 3 weeks later were then pooled
and stored in liquid nitrogen.All retroviral vectors were modified from pLXSN (Miller
and Rosman, 1989). HIV-1 LTR DNA was PCR amplified Target Jurkat cells were subsequently transduced by
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incubating with the conditioned medium containing dif- 1 volume of prechilled 201 SSC, the RNA samples were
applied, under vacuum, onto Hybond C-extra membraneferent recombinant defective retroviruses in the presence
of 4 mg/ml of polybrene (Sigma). Twenty-four hours after (Amersham) using a BRL HYBRI.Dot 96-well filtration
manifold, and fixed under vacuum at 807 for 2 hr. Thecoculture, the cells were transferred into RPMI selection
medium (RPMI-1640 growth medium with 400 mg/ml ac- membrane was prehybridized for 5 hr and hybridized for
16 hr at 507 in 51 SSPE (0.9 M NaCl, 40 mM sodiumtive Geneticin). The medium was replaced twice a week
thereafter. Resistant Jurkat cells selected by growth in phosphate, pH 7.7, 5 mM EDTA), 51 Denhardt’s, 0.5%
SDS, 80 mg/ml denatured salmon sperm (ss) DNA, andselection medium were pooled for further experiments
without cell cloning. 2 pmol of 32P 5*-end-labeled oligonucleotide probe. The
probe contained sense sequence spanning the 3* splice
junction shared by tat and rev RNA (see Table 1). AfterRNA analysis
hybridization, the membrane was washed in 61 SSPE,
0.1% SDS at 557 for 2 hr with three changes of the wash-Total RNA from parental or transduced Jurkat cells was
extracted by the acidic guanidium thiocyanate–phenol– ing solution and was exposed to Phosphora Imager
screen for 5 hr and then to Kodak Bio Max film at 0707chloroform method (Chomczynski and Sacchi, 1987). The
cytoplasmic RNA was prepared by NP-40 lysis and SDS – for 12 to 18 hr. Antisense RNA standards were synthe-
sized using the MEGAscipt T7 in vitro transcription kitproteinase K digestion (Gilman, 1992). To remove poten-
tially contaminating DNA, all the RNA samples were di- (Ambion, Inc.) using the recombinant pBluescript II (KS0)
digested with the appropriate restriction enzyme as tem-gested with DNase. Five micrograms of RNA was mixed
with 3 units of RNase-free DNase (Boehringer Mann- plates. The in vitro-transcribed RNA was digested with
RNase-free DNase, extracted with phenol–chloroformheim), 12 units RNasin (Promega), 10 mM DTT, 100 mM
sodium acetate, 5 mM magnesium sulfate in a 100-ml twice, precipitated in ethanol, and resuspended in DEPC-
treated water. The concentration of RNA was estimatedreaction, incubated at 377 for 20 min. Under the defined
conditions 1 unit of the RNase-free DNase had been by spectrometry, converted into copy number per microli-
ter, and used as standard. The diluted RNA standardsshown in our own experiments to digest 1 mg of plasmid
DNA to completion in 15 min at 377. were supplemented with cellular RNA from parental Jur-
kat cells at concentration of 1 mg/ml. The same mem-Antisense RNA and HIV RNA were detected by RNA-
based PCR. Extracted RNA (5 mg) was reverse tran- branes were stripped off the tat and rev probe by boiling
in 0.5% SDS for 10 min and reprobed with a b-actin probescribed (RT) in the presence of sense primer (for tat or
rev antisense RNA) or the antisense primer (for HIV gag (b-act 2; Table 1).
RNA or b-actin RNA), using M-MLV reverse transcriptase
(Gibco BRL) and conditions recommended by the manu- DNA analysis
facturer. One-fourth (5 ml) of the resultant cDNA was
amplified separately for antisense RNA, gag RNA, or b- Extrachromosomal DNA and chromosomal DNA
were purified by the Hirt method (Hirt, 1967; Li andactin RNA after heating to 657 for 10 min to inactivate
residual reverse transcriptase. A 50-ml reaction mixture Burrell, 1992). Total cellular DNA was prepared by pro-
teinase K digestion. Briefly, the cells were pelleted bycontaining 5 ml cDNA, 50 mM KCl, 10 mM Tris–HCl, pH
8.3, 1.5 mM MgCl2 , 200 mM each dNTP, 1.25 unit Taq microfuging. For 10
6 cells, 100 ml of digestion buffer
containing 50 mM KCl, 10 mM Tris – HCl, pH 8.3, 1.5DNA polymerase (Perkin –Elmer Cetus), and 50 pmol
each appropriate primer (see Table 1) was denatured at mM MgCl2 , 0.5% Triton X-100, and 200 mg/ml protein-
ase K was used. After incubation at 567 for 1 hr and947 for 3 min, then incubated at 947 and 647 for 30 sec
and 2 min, consecutively, for 40 cycles in a DNA thermal subsequent heating at 957 for 10 min to inactivate the
enzyme, 5 ml of the DNA preparation was used directlycycler (Perkin–Elmer Cetus). Ten-microliter portions of
each PCR product were electrophoresed on 1.5% agar- for PCR detection of HIV-1 gag DNA and cellular b-
globin DNA. The thermal cycle program was the sameose gel. DNA was visualized by UV fluorescence after
staining with ethidium bromide. The RT-PCR reaction as that for RT-PCR. To prevent contamination, all the
tubes containing the DNA samples were opened onlywas strand specific since no specific band could be am-
plified when antisense primers instead of sense primers inside a dedicated laminar flow hood. One-fifth (10 ml)
of each PCR product was resolved by electrophoresisfor HIV tat or rev were used in the RT reaction with
samples containing only antisense transcripts. on a 1.5% agarose gel and transferred to Hybond N/-
extra membrane (Amersham) using conditions recom-Quantitation of antisense RNA was performed using
RNA dot blot hybridization. Total cellular RNA (15 mg) mended by the manufacturer. The membrane was pre-
hybridized for 5 hr and hybridized for 18 hr at 507 in 51was dissolved in 300 ml of dot blot buffer containing 65%
formamide, 0.75% formaldehyde, and 11 MOPS buffer, SSPE, 51 Denhardt’s, 0.5% SDS, 80 mg/ml denatured
ssDNA, and 2 pmol of 32P 5*-end-labeled gag-specificdenatured by heating at 657 for 5 min. After mixing with
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TABLE 1
Sequences of Oligonucleotide Primers and Probes
tRNAmet primers
TR 1 (/) 5* gaa ttc gca acc tgt ggt agc caa aga 3*
TR 2 (/) 5* aat cga tgg ggt ttc gat cca tcg acc tct 3*
HIV-1 gag primers and probe
Gag 5 (/) 5* agt acc ctt cag gaa caa ata gga 3*
Gag 6 (0) 5* cat gct gtc atc att tct tct agt gtc 3*
Gag probe (0) 5* tct ggg ttc gca ttt tgg aca aac aag 3*
Human b-globin primers
b-glo 1 (/) 5* caa ctt cat cca cgt tca cc 3*
b-glo 2 (0) 5* gaa gag cca agg aca ggt ac 3*
Tat primers
Tat 1 (/) 5* cgg cgg ccg cga ggg gcg gcg act g/aat tgg gtg tcg aca tag cag 3*
Tat 2 (0) 5* gct cta gag tct ctc tcc acc ttc tt 3*
Rev primers
Rev 1 (/) 5*cgg cgg ccg cga ggg gcg gcg act g/gca tct cct atg gca gga aga 3*
Rev 2 (0) 5* gct cta gat gag caa gct aac agc act a 3*
tat and rev probe
TRN 3 (/) 5* ttc tct atc aaa gca acc cac ctc cca atc ccg ag 3*
Human b-actin primers
b-act 1 (/) 5* ctc acc atg gat gat gat atc gcc gcg ctc 3*
b-act 2 (0) 5* cgc gct cgg tga gga tct tca tga ggt agt 3*
oligonucleotide probe (see Table 1). After hybridization precipitation as mentioned previously. Forty-eight hours
after removing the precipitate, the conditioned mediumthe membrane was washed in 61 SSPE, 0.1% SDS at
557 for 2 hr with three changes of the washing solution containing the virus was collected and stored at 0707.
An aliquot of the virus was thawed and the TCID50 wasand exposed to Kodak Bio Max film at 0707 for 4 to 24
hr. The HIV gag DNA standard was derived from a determined by infectivity assay (Johnson et al., 1990).
Transduced Jurkat cells were challenged with HIV-1plasmid containing full length HIV gag. The linearized
plasmid DNA was diluted in TE containing Jurkat cellu- NL43 at a m.o.i. of 0.01 for 24 hr at 377. The infected cells
were then washed twice with serum-free RPMI mediumlar DNA.
and resuspended in growth medium. The culture super-
Thymidine uptake and CD4 expression natant was collected for p24 assay twice a week from 1
to 4 weeks postchallenge (pc), once a week from 5 to
Rate of DNA synthesis was estimated by the amounts 10 weeks pc, once every 2 weeks 10 to 20 weeks pc.
of [3H]thymidine incorporated into the cells. Briefly, pa- HIV p24 concentration in the supernatant was deter-
rental Jurkat cells and transduced cells were seeded into mined by using a commercial HIV-1 p24 ELISA kit (Du-
quadruplicate wells of a 96-well cell culture plate at 2 1 pont). p24 expressed in HIV-1-infected cells was deter-
105 cells in 200 ml of RPMI growth medium per well. mined by immunofluorescence using the protocol de-
Twenty microliters of [3H]thymidine (Amersham) at a con- scribed before (Peng et al., 1995). Briefly, 9 weeks after
centration of 50 mCi/ml in RPMI growth medium was HIV challenge, an aliquot of cells (1 1 105) was spotted
added to each well at the time of plating to give a final onto pH17 slides (Wellcome), air-dried, and fixed with
concentration of 4.5 mCi/ml. After 23 hr the cells were acetone:methanol (1:1) at 0207 for 7 min. After treating
harvested onto filter paper with a semiautomatic cell col- with blocking agent containing 5% normal goat serum,
lector. The radioactivity of the filter was measured in a the cells were incubated with mouse monoclonal anti-
scintillation spectrometer. Expression of surface CD4 on HIV-1 p24 antibody (Biodesign) at 47 for 18 hr, then with
transduced cells was monitored by flow cytometry (Sat- FITC-conjugated sheep anti-mouse IgG (Biodesign) at
tentau et al., 1986). 257 for 1 hr. After mounting in Vectorshield (Vector Labo-
ratories, Inc.), the preparations were examined by epiflu-
HIV-1 challenge and p24 assay
orescence.
Virus stock HIV-1 NL43 was produced by transfecting
Virus rescueHeLa–tat cells, a clonal HeLa derivative constitutively
expressing HIV-1 tat (unpublished data), using an infec- Transduced Jurkat cells that had been infected with
HIV-1 20 weeks previously were mixed with parental Jur-tious provirus clone, pNL43. Briefly, the subconfluent
HeLa–tat cells were transfected by calcium phosphate kat cells at a ratio of 1:2. After coculture for 3 days,
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another aliquot of parental Jurkat cells were added at a pLSNPaL&rev (10) would have similar anti-tat and anti-
rev properties, but because they also contained anti-ratio of 1:1. Every week after the starting of the coculture
an aliquot of 106 cells was taken for HIV DNA PCR. sense sequence complementary to the 5* untranslated
leading sequence these antisense RNAs may also inter-
act with all HIV mRNA at the 5* untranslated leadingOligonucleotide primers and probes
sequence.
All the oligonucleotides were synthesized by Bresatec. The group 1 and group 2 vectors described above are
Their sequences were listed in Table 1. double-copy vectors in which the antisense RNA expres-
sion cassettes were placed inside the U3 region of the
RESULTS 3* LTR of the retroviral vectors. In the transduced cells
the tRNA-antisense tat or rev template would be dupli-Construction of anti-tat or anti-rev expression vectors
cated and present at both LTRs of the proviral DNA. Oneand transduction of Jurkat cells
copy of the antisense RNA expression cassette would
therefore be located outside the retroviral transcriptionWe constructed a series of retroviral vectors in which
the expression of anti-tat or anti-rev RNA was placed unit (i.e., upstream the 5* MLV LTR promoter).
We also placed the tRNA-antisense tat or rev expres-under control of one of three different promoters in the
context of double-copy or single-copy retroviral vectors sion cassettes inside the retroviral transcription unit (be-
hind the 5* MSV LTR). Such conventional single-copy(Fig. 1). In the first group of vectors (Fig. 1, 1–6), anti-
sense RNA expression was placed under the control of vectors driven by the tRNA promoter, pLPaL&tatSN and
pLPaL&revSN (Fig. 1, 13 and 14) were included to exam-the HIV LTR promoter. The cells transduced by these
vectors were expected to express only very low levels ine the relative advantage of double-copy vector over
single-copy vector. In the other set of single copy vectors,of antisense RNA before HIV infection. Upon HIV infec-
tion, tat produced by the virus would transactivate the pLaL&tatSN and pLaL&revSN (Fig. 1, 11 and 12), the
expression of antisense RNA was placed directly underHIV promoter and drive the transcription of antisense
RNA. pLSNHaT (1) and pLSNHaR (2) contain a full length the control of the MLV LTR promoter. Two control vectors,
pLSNP and pLPSN (Fig. 1, 15 and 16), which had theHIV-1 LTR as the promoter, while pLSNdHaT (3) and
pLSNdHaR (4) contain a deleted HIV-1 LTR from which same retroviral vector backbone and tRNA promoter as
the double-copy or single-copy vector except that theythe 5* negative regulatory element (NRE) located up-
stream of position 0155 was deleted using a protocol did not contain the tat or rev antisense sequences, were
included to rule out nonspecific activity of the vectors.described previously (Peng et al., 1995). The 5* NRE may
inhibit the activity of HIV promoter (Rosen et al., 1985; The retrovirus vectors described above were con-
verted to corresponding defective retrovirus by transfect-Lu et al., 1989). Its removal may augment the expression
of antisense RNA driven by HIV LTR. pLSNHcaT (5) and ing the vector DNA into an amphotropic packaging cell
line, PA317. Two days after transfection, the conditionedpLSNHcaR (6) contain the HIV LTR plus the main se-
quence of the HIV packaging signal (c) according to medium containing the defective retrovirus was used to
transduce Jurkat cells. Jurkat transductants were se-Hayashi et al. (1992). Antisense RNA expressed by these
vectors will contain positive-sense c sequence at the 5* lected in medium supplemented with Geneticin for 23–
55 days until the pooled resistant cells reached a totalend and therefore would also be able to compete with
HIV RNA for packaging into the virion. of 5 1 106 cells and were then cryo-stored in liquid nitro-
gen. T cells transduced by pLSNPaT and pLSNPaR tookIn the second group of constructs, the expression of
antisense RNA was driven by human tRNAmet promoters only 23 days, while pLSNPaL&rev took 55 days to reach
a total of 5 1 106 cells. Assuming the efficiency of trans-(Fig. 1, 7–10). The tRNA promoter sequence (180 bp)
from which the termination and processing sequence duction was the same among different vectors, the time
needed for the transduced cells to reach the same num-was deleted, was PCR amplified from Jurkat cellular DNA.
The DNA sequence was verified to be identical to the ber may have reflected different titers of defective recom-
binant viruses.promoter sequence of human tRNAmet reported by Santos
and Zasloff (1981). The tat or rev antisense sequences We could not select out any Geneticin-resistant cells
from T cells transduced by pLSNdHaT and pLSNdHaRwere inserted between the transcribed region of tRNA
and the added tRNA transcription termination signal. This supernatant, despite the fact that resistant PA317 cells
transfected by these two vectors had been selected.arrangement should result in the formation of chimeric
RNA transcripts (Adeniyi-Jones et al., 1984). Antisense Transcriptional interference (Cullen et al., 1984;
Proudfoot, 1986) may explain the different results in theRNA expressed by pLSNPaT (7) and pLSNPaR (8) were
expected to interact with the entire coding sequences of transduced cells versus transfected cells. In transduced
T cells the transcription of the Neor gene might havetat or rev RNA (see Peng et al., 1995, for exact sequence).
Antisense RNAs expressed by pLSNPaL&tat (9) and been suppressed by the dominant HIV dLTR promoter
AID VY 7945 / 6a18$$$241 05-16-96 05:34:22 viras AP: Virology
382 PENG ET AL.
AID VY 7945 / 6a18$$7945
05-16-96 05:34:22 viras AP: Virology
383DESIGN OF VECTOR AFFECTS PROTECTION AGAINST HIV-1
residing in the 5* LTR upstream of the Neor gene expres-
sion cassette; in contrast, in PA317 cells transfected by
the same two vectors, the only HIV dLTR promoter was
located downstream of the Neor gene expression cas-
sette, and for this reason might not interfere with tran-
scription of the neomycin-resistant gene.
Expression of antisense RNA in transduced Jurkat
cells
To simplify the description of all the tat or rev antisense
expression vectors and their transductants we renamed
the antisense RNA expression vectors that would be
used in further experiment (Fig. 1). The corresponding
Jurkat transductants would be named after the vector;
for example, cells transduced by anti-tat 1 were named
J anti-tat 1.
The expression of antisense RNA in Jurkat transduc-
tants was assessed initially by RNA-based PCR. Total
cellular RNA was isolated from Jurkat transductants after
Geneticin selection. The RNA preparation was digested
with RNase-free DNase to eradicate potentially contami-
FIG. 2. Antisense RNA expression in Jurkat cells transduced by
nating DNA. The first-strand cDNA was synthesized by retroviral vectors. Total cellular RNA or cytoplasmic RNA were ex-
RT using the downstream-sense oligonucleotide specific tracted from Jurkat cells transduced by retroviral vectors anti-tat 1
to 6, anti-rev 1 to 6, and control vectors C1 and C2. Antisense RNAfor tat or rev as primer (sense or antisense is related to
was detected by RT-PCR and ethidium bromide staining (A – C) orthe original sequence of HIV RNA). The resultant DNA
quantitated by RNA dot blot (D). (A) Total antisense RNA in trans-was then amplified by PCR. No corresponding DNA band
duced cells 8 weeks after transduction. (B) Cytoplasmic antisense
could be amplified from the sample without first being RNA in transduced cells 9 weeks after transduction. (C) Total anti-
subjected to RT. Using the antisense oligonucleotides sense RNA in transduced cells that had been challenged with HIV
for 16 weeks. (D) Quantitation of antisense RNA expression in trans-as the RT primers in the same way did not give rise to
duced cells 12 weeks after transduction. Four series of twofold dilu-any specific band after PCR (data not shown). Collec-
tions starting from 15 mg cellular RNA per dot were included fortively, these controls demonstrated the RT-PCR was RNA
each sample. Therefore, from bottom to top, the four dots of each
strand specific. sample contained 15, 7.5, 3.75, and 1.875 mg of total cellular RNA.
Figure 2A shows the expression of specific antisense Abbreviations are asRNA, antisense RNA of tat or rev; b-actin, b-
actin RNA; S, copy number standard of antisense RNA, from bottomRNA in Jurkat cells transduced with each construct. Cells
to top, each dot contained 1.5 1 108, 7.5 1 107, 3.75 1 107, and 1.88transduced by anti-tat 1 or 2 and anti-rev 1 or 2 expressed 1 107 copies of antisense RNA, respectively; C, control 1.only low levels of antisense RNA. That was consistent
with the observation that the basal promoter activity of
HIV LTR is low (Fisher et al., 1986; Dayton et al., 1986). procedure. The patterns of antisense RNA in cytoplasm
(Fig. 2B) were similar to those in total cellular RNA (Fig.Antisense RNA could be easily detected in cells trans-
duced by anti-tat 3, 4, 5, or 6 or anti-rev 3, 4, 5, or 6 2A), suggesting that all the antisense RNA expressed
under the control of the tested promoters could be suc-although the level of antisense RNA in J anti-tat 4 was
lower compared to others. cessfully transported into cytoplasm.
The expression level of tat or rev antisense RNA wasTo examine whether the antisense RNAs were trans-
ported into the cytoplasm of transduced cells, we iso- further quantified by RNA dot blot using in vitro-tran-
scribed tat or rev antisense RNA as a copy number stan-lated cytoplasmic RNA from the cells. After DNase treat-
ment, the antisense RNA was detected using the same dard (Fig. 2D). The RNA blots were probed with a 32P-
FIG. 1. Structure of antisense RNA expression vectors (not drawn to scale). Abbreviations are LTR (5*), Moloney murine sarcoma virus (MSV) 5*
long terminal repeat; LTR (3*), Moloney murine leukemia virus (MLV) 3* long terminal repeat, which was modified in vectors 1 to 10 and 16 as
individually indicated; SV, simian virus 40 early promoter; NEO, neomycin phosphotransferase gene; HIV LTR, long terminal repeat of HIV (1–684);
HIV dLTR, HIV LTR with a deletion of the 5* negative regulatory element (i.e., bases 286–684); HIV LTRc, HIV LTR plus the main sequence of HIV
RNA packaging signal (i.e., bases 1–800); tRNA-P, human tRNAmet promoter; TT, RNA polymerase III transcription termination signal; a-tat or a-rev,
antisense templates of HIV tat or rev coding sequences; a-L&tat or a-L&rev, antisense template of HIV tat or rev coding sequences plus the 5*
untranslated leading sequence of HIV mRNA (bases 454–743). HIV sequence numbering system is based on the sequence of HIV NL43 (Genbank
Accession No. M19921).
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TABLE 2
Antisense RNA Expression and HIV Resistance in Cells Transduced by Anti-tat and Anti-rev Expression Vectors
HIV DNAb
p24 IFA HIV RNA Virus rescue
Vectors asRNAa 4 wpc 15 wpc 23 wpc p24 ELISA 9 wpc 14 wpc 20 wpc
Anti-tat 1 5.38 103 0 0 0 0 0 0
Anti-tat 2 8.34 102 0 0 0 0 0 /
Anti-tat 3 59 0 0 0 0 0 0 0
Anti-tat 4 56 0 0 0 0 0 0 0
Anti-tat 5 107 0 103 103 /(from 5 wpc) / / /
Anti-tat 6 76.4 103 103 103 /(from 2 wpc) / / /
Anti-rev 1 0.99 103 0 0 0 0 0 /
Anti-rev 2 4.29 103 0 0 0 0 0 /
Anti-rev 3 45.4 0 0 0 0 0 0 0
Anti-rev 4 46.5 103 0 0 0 0 0 0
Anti-rev 5 223 2 1 102 1 30 0 0 / /
Anti-rev 6 63.5 103 103 103 /(from 10 wpc) 0 / /
Control 1 0 103 103 103 /(from 1.5 wpc) / / /
Control 2 0 103 103 103 /(from 2 wpc) / / /
a Antisense RNA copies (1106) in 10 mg of total cellular RNA prior to HIV challenge.
b HIV DNA copies in 5 1 104 cells; wpc, weeks post HIV challenge.
labeled sense oligonucleotide complementary to the 3* challenge. There was no similar band in the two control
cultures which had been subsequently infected by HIVsplice junction sequences shared by both tat and rev
mRNAs (Table 1). The radioactive signal of each RNA and expressed HIV RNA, again indicating that the proto-
col used was specific for the antisense RNA. This resultdot was analyzed on a Phosphora Imager (Molecular
Dynamics, Sunnyvale, CA) and converted to copy number demonstrated that the expression of antisense RNA in
Jurkat cell was stable even without the selection pres-of antisense RNA per 10 mg of total cellular RNA by
comparing the intensity of radioactive signals with those sure of Geneticin. These results, if applicable to primary
cells in vivo, would be of importance for potential geneof the standard RNA after subtracting the background
signal equivalent to that in the control (C) and normalized therapy against HIV infection.
with the amount of RNA loaded as indicated by the signal
of the b-actin probe. As shown on Table 2, the relative Expression of tat and rev antisense RNA did not alter
levels of antisense RNA expression among the Jurkat the rate of cell proliferation or surface CD4
transductants shown by RNA dot blot were broadly simi- expression
lar to those shown by RT-PCR. As predicted, anti-tat 1
and 2 and anti-rev 1 and 2 transductants (in which the To assess the impact of antisense RNA expression on
cell proliferation, [3H]thymidine incorporation assay wasantisense RNA expression was controlled by HIV LTR
promoter) expressed only low levels of antisense RNA, performed to determine the rate of DNA synthesis, which
correlates with cell proliferation. The rates of [3H]-less than 107 copy per 10 mg RNA. On the contrary, anti-
tat 5 and anti-rev 5 transductants in which the expression thymidine incorporation in Jurkat cells transduced by
anti-tat 1 to 6 and anti-rev 1 to 6 were similar and wereof antisense RNA was controlled by the MLV LTR pro-
moter expressed the highest level of antisense RNA, up not significantly different from those of the parental cells
or cells transduced by control vector only (not shown).to 108 and 2.2 1 108 copy per 10 mg RNA, respectively.
The levels of antisense RNA expression in the Jurkat The effects of antisense RNA expression on cell viability
and cell proliferation were also monitored by trypan bluetransductants were consistent after long periods of in
vitro culture for up to 7 months (data not shown). exclusion assay. Under similar cell culture conditions, no
significant differences were found in the number of viableTo assess antisense RNA expression after HIV infec-
tion, we isolated total cellular RNA from the transduced cells or in the rate of cell proliferation from cultures of
parental cells and cells expressing antisense vectors orcells 16 weeks after HIV challenge and assayed anti-
sense RNA as above. It is worth mentioning that after control vectors in a 4-week observation (data not shown).
These results indicate that the expression of anti-tat andHIV challenge all the transduced cells had been cultured
in RPMI growth medium without Geneticin. As shown in anti-rev RNA did not have substantial impact on the prolif-
eration of these cells.Fig. 2C the pattern and level of antisense RNA expression
was similar to or higher than that in the cells before HIV The effect of antisense RNA expression on cell surface
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to HIV infection. Jurkat cells transduced by anti-tat 5 or
anti-rev 6 were partially resistant to HIV infection as evi-
denced by the delayed detection of HIV p24 at 5 or 10
weeks postchallenge. We could not detect any HIV p24
in Jurkat cells transduced by anti-tat 1, 2, 3, or 4 or anti-
rev 1, 2, 3, 4, or 5 in a 20-week period of observation.
This suggested that no detectable level of virus was re-
leased from the cells, but did not rule out the possibility
that virus could replicate inside the cells but could not
be released. To test this possibility, we performed immu-
nofluorescence to detect p24 at 9 weeks after HIV chal-
lenge. The results showed that all the cultures that re-
leased p24 to the supernatant also had viral antigen in
20 to 30% of the cell population, and cells without p24
production in the culture medium did not have detectable
specific immunofluorescence (data not shown).
We further tested Jurkat transductants for positive-
sense HIV RNA 14 weeks after HIV challenge. Total
cellular RNA was extracted from the cells by the gua-
nidium thiocyanate method. The RNA samples were
treated with RNase-free DNase before being used for
RT-PCR. The cells positive for HIV p24 were all positive
for HIV gag transcript (control cells and cells trans-
duced by anti-tat 5 or 6 or anti-rev 6) (Fig. 4). In contrast,
cells negative for HIV p24 did not produce detectable
levels (one copy per cell) of HIV gag RNA except cellsFIG. 3. Inhibition of HIV replication in transduced T cells expressing
antisense RNA. Cell culture supernatants were collected at designated transduced by anti-rev 5, which were positive for viral
time points after HIV-1 challenge of Jurkat cells transduced by (A) anti- RNA but negative for p24.
tat 1 to 6, (B) anti-rev 1 to 6, and control 1 and 2. p24 concentration
was determined by ELISA. The results shown on the graph are the
Long-term protection against HIV infection by anti-tataverage values of two experiments. p24 levels exceeding 100 ng/ml
(for J anti-tat 6, J control 1, 2) or 1000 pg/ml (for J anti-tat 5 and J anti- and anti-rev expression was associated with inhibition
rev 6) were not further quantitated. of HIV DNA production
The HIV DNA levels in the transduced T cells were
CD4 level was evaluated using flow cytometry. The levels monitored every 3–4 weeks after HIV challenge using a
of CD4 expression within each culture of transduced highly sensitive semiquantitative PCR. To obtain more
cells as well as parental cells were quite variable, as accurate quantitation and avoid cross-contamination, we
indicated by the extent of standard deviation in each used a simple and highly reproducible protocol to pre-
group. However, the overall levels of expression of cell pare the DNA samples from infected cells (see Materials
surface CD4 were not significantly altered in the cells and Methods). One million cells were harvested, lysed
transduced by antisense RNA expression vectors, com- in Triton X-100, and digested with proteinase K. After
pared with that in the parental cells (not shown). inactivating the enzyme by heating, an aliquot of the di-
Long-term protection against HIV challenge in Jurkat
cells by anti-tat or anti-rev RNA
Jurkat cultures transduced with each of the 14 vectors
were separately pooled and challenged with HIV NL43
at a m.o.i. of 0.01. Figure 3 shows the replication of HIV
in each culture as determined by the level of p24 in the
culture medium. The two control cell populations showed
FIG. 4. Inhibition of HIV transcription by antisense RNA expression.marked cytopathogenic change within 2 weeks after HIV-
Total cellular RNA was isolated from the transduced cells 14 weeks1 infection, coincident with the release of p24 into the
after HIV-1 challenge. HIV-1 gag RNA (gag) was detected using RT-
culture supernatant, indicating HIV-1 replication. Jurkat PCR. b-Actin RNA (b-actin) was included as a control in RT-PCR using
cells transduced by anti-tat 6 behaved similarly to the the same RNA samples to rule out the presence of possible RT or PCR
inhibitors and the variation of RNA input in the samples.two control cells, indicating that they were not resistant
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10 weeks of infection. In J anti-rev 4 only very low level
of HIV DNA (1 copy per 5 1 104 cells) was detected
from 6 to 10 weeks of infection, and no HIV DNA was
detected from 12 weeks postchallenge. The HIV DNA
detected at the early stage of HIV infection was found
mostly to be extrachromosomal DNA (data not shown).
The results indicate that HIV DNA synthesized in J anti-
tat 2 and J anti-rev 1, 2, and 4 may be unable to integrate,
and therefore DNA could not last very long in the culture.
(iv) Complete protection. We could not detected any HIV
DNA from J anti-tat 3 and 4 as well as J anti-rev 3 at all
the time points tested, and these cultures showed no
other markers of HIV infection.
The inability to detect viral DNA by highly sensitive
PCR from some of the transduced cells after HIV infection
suggested the following two possibilities: (1) the chal-
lenge virus had not established infection and had been
FIG. 5. Inhibition of HIV DNA synthesis by antisense RNA expression. inactivated or (2) HIV infection was established but was
Total cellular DNA was prepared from transduced, HIV-challenged cells suppressed to a level so low that residual viral DNA
and subjected to PCR using primers specific for HIV-1 gag conserved could not be detected by PCR. To test these two possibili-
sequence. The PCR products were resolved on agarose gel and blotted
ties we performed virus rescue experiments by cocultur-onto nylon membrane and probed with HIV gag-specific probe. Plasmid
ing susceptible Jurkat cells with transduced cells thatDNA containing the full length HIV gag DNA was used as a copy
number standard. An aliquot of cellular DNA from each sample was had been challenged with HIV 20 weeks previously. If
PCR amplified for b-globin DNA to rule out the presence of PCR inhibi- low-level persistent HIV infection was present in the
tors and the variation of DNA input. (A) HIV gag DNA detected on 18 transduced cell population, the virus should be able to
weeks post HIV challenge. (B) HIV gag DNA detected on 23 weeks
infect and replicate in the permissive parental Jurkat cell,post HIV challenge. (C) HIV gag DNA at 2 weeks after virus rescue by
resulting in detectable level of HIV DNA. Total cellularcocultivation with parental Jurkat cells.
DNA was prepared weekly during a 2-week period of
coculture and examined by PCR. Two weeks after cocul-
ture low levels of HIV DNA could be detected from J anti-gested mixture was used directly for PCR. The PCR prod-
ucts were detected by Southern blot and hybridization tat 2 and J anti-rev 1 or 2, but not from J anti-tat 1, 3, or
4 or J anti-rev 3 or 4 (Fig. 5C). These results demonstratedwith a HIV-1 gag-specific oligonucleotide probe. Two rep-
resentative results are shown in Fig. 5. Four patterns of that Jurkat cells expressing anti-tat 3 or 4 and anti-rev 3
or 4 did not support maintenance of any residual HIVprotection from HIV infection were observed (Table 2): (i)
No protection. The two control cultures and J anti-tat 6 infectivity and that although J anti-tat 2 and J anti-rev 1
or 2 allowed initial infection, these cells had remainedand J anti-rev 6 harbored high levels of HIV DNA (103
copy per 5 1 104 cells) at all time points tested, in good resistant to further detectable virus replication during 20
weeks of continuous low-level viral challenge.agreement with the p24 and HIV RNA results except for
J anti-rev 6, which was p24 negative for the initial 10
weeks of infection. This indicates that J anti-tat 6 was DISCUSSION
not protected against HIV-1 infection while J anti-rev 6
showed transient suppression of HIV gene expression Twelve retroviral vectors expressing tat or rev anti-
sense RNA driven by different promoters and in the con-only. (ii) Partial protection. In J anti-tat 5, the onset of HIV
replication was delayed but was established; markers of text of single- or double-copy retrovirus vectors were
constructed and used to transduce Jurkat cells. Anti-virus replication were positive. J anti-rev 5 contained HIV
DNA (fluctuating) and HIV RNA, while p24 protein synthe- sense RNA was expressed in cultures transduced by
most of the constructs, and cell proliferation and cellsis was not detectable. (iii) Early HIV DNA synthesis fol-
lowed by protection. A high level (103 copy per 5 1 104 surface CD4 expression were not affected. The highest
levels of antisense RNA were expressed in the cellscells) of HIV DNA was detected in J anti-tat 1 and 2 and
J anti-rev 1, 2, and 4 at the beginning of HIV infection. transduced by those tat or rev antisense RNA-expressing
vectors driven directly by the MLV LTR promoter (anti-tatMost of the J anti-tat 1 cells were killed without discern-
ible syncytia within 6 weeks after infection. Cells propa- 5, anti-rev 5). However the J anti-tat 5 cells were only
partially resistant to HIV infection, since delayed HIV rep-gated from the survival cells were free of HIV DNA. No
cell killing was detected in J anti-tat 2 and J anti-rev 1 or lication was seen (Fig. 3A). In J anti-rev 5 cells the produc-
tion of p24 was suppressed although the infection had2 and the cells contained no detectable HIV DNA after
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been established as shown by the presence of HIV provi- target sequence itself might affect the efficacy of the
antisense RNA. These characters (size, accessory se-ral DNA and gag RNA. Differences between tat and rev
antisense RNA in the patterns of resistance to HIV infec- quences, etc.) should be primarily determined by the de-
sign of the retroviral expression system. The size of thetion may have reflected the functional differences be-
tween these two proteins in the HIV replication cycle. antisense transcript may affect its ability to get access
to its target RNA. Smaller antisense RNA expressed un-Tat is required for maximal level of HIV transcription and
therefore is probably more critical in the establishment der the control of tRNA promoters may be more efficient
because it contains less accessory sequence (such asof HIV infection; in contrast, rev exerts its function post-
transcriptionally by increasing the transportation of un- the untranslated leading sequence and poly(A) tail on
mRNA transcribed by RNA polymerase II). The accessoryspliced and singly spliced HIV mRNA to the cytoplasm,
therefore enhancing the production of HIV structural pro- sequence associated with the antisense RNA may have
an impact on the compartmentalization of the effectorteins (Felber et al., 1989; Malim et al., 1989). Our results
indicate that high-level expression of anti-rev antisense RNA molecules. Compartmentalization of mRNA has
been shown in a number of somatic cell types (St. John-RNA driven by MLV promoters could not prevent synthe-
sis of proviral DNA or viral RNA transcription, but could ston, 1995). HIV transcripts may be localized in some
part of the subcellular structure which may not be easilysuppress the production of structural proteins.
Anti-tat and anti-rev antisense RNA expressed under accessed by antisense RNA transcribed by RNA poly-
merase II, as in J anti-tat 5, but may be readily accessiblethe control of HIV-1 LTR promoter (anti-tat 1, 2 and anti-
rev 1, 2) could not prevent the establishment of a very by antisense RNA driven by tRNA promoter (as J anti-tat
3). The presence of tRNA sequences at the 5* end of thelow level persistent HIV infection as evidenced by the
presence of infectious virus rescued at 22 weeks, but antisense RNA transcripts may also affect their capability
to interact with the currently undefined stages of viralthe infection was suppressed to the extent that it was
undetectable in all other assays. This result suggests gene expression targeted by these inhibitors. Further
studies are in progress to examine these aspects.that HIV-regulated expression of anti-tat or anti-rev anti-
sense RNA was not efficient enough to prevent the estab- In conclusion our results demonstrate that of those
promoters examined, the best promoter for achievinglishment of HIV infection. This is not unexpected because
in cells transduced by these vectors, antisense RNA ex- antisense RNA-mediated inhibition of HIV replication is
human tRNAmet promoter. The antisense RNA expressionpression would require transactivation by tat, which
could be produced only after HIV infection. To prevent cassette should be placed in the context of a double-
copy vector to avoid possible upstream promoter interfer-the establishment of HIV infection the cells would need
to express antisense RNA constitutively, as in the case ence or dominance. Tat or rev full length antisense RNA
driven by human tRNAmet promoter in the context of aof RNA expression driven by human tRNAmet promoters
located outside the retroviral transcription unit (anti-tat 3 double-copy vector can confer long-term protection
against HIV infection by preventing the establishment ofand anti-rev 3).
When the tRNAmet-antisense RNA cassettes were HIV infection. These vectors may be useful for future
gene therapy against HIV infection.placed within the MLV transcription units (e.g., J anti-tat
6 and J anti-rev 6), most of the antisense RNA expressed
in transduced cells would probably be driven by the MLV ACKNOWLEDGMENTS
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